Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes

AstraZeneca1,064 enrolled

Overview

The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment (statin or combination) reaching the LDL-C goals according to the updated 2004 National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines.

MC MD

Study Type

OBSERVATIONAL

Enrollment

1,064

Conditions

Dyslipidemia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Provision of subject informed consent, Female or male aged = 18 years * Patients eligible for treatment of dyslipidemia with statins, according to the current guidelines NCEP ATPIII about Dyslipidemias and Atherosclerosis Prevention Receiving lipid-lowering drug treatment for at least 15 days. Exclusion Criteria: * Involvement in the planning and conduct of the study (applies to either AstraZeneca staff or staff at the study site). * Previous enrolment or randomisation of treatment in the present study * Participation in a clinical study during the last 90 days

Outcomes

Primary Outcomes

The number (#) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines.

Time frame: 1 year

The percent (%) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines.

Time frame: 1 year

Secondary Outcomes

The number of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets

Time frame: 1 year

The number of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1

Time frame: 1 year

The number of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year

Time frame: 1 year

The percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets

Time frame: 1 year

The percent of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1

Time frame: 1 year

The percent of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.